P2 Receptors in Bone - Modulation of Osteoclast Formation and Activity via P2X7 Activation

Critical Reviews in Eukaryotic Gene Expression

Volumn 13, Issue 2-4 SPEC. ISS., 2003, Pages 237-242

  Gartland, Alison ^a   Buckley, Katherine A ^b   Hipskind, Robert A ^c   Bowler, Wayne B ^d   Gallagher, James A ^b  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c CNRS   (France)

^d Strakan Pharmaceuticals   (United Kingdom)

Author keywords

Apoptosis; ATP; Multinucleation; Osteoblast; Osteoclast; P2 receptors

Indexed keywords

ADENOSINE TRIPHOSPHATE; NUCLEOTIDE; PURINE P2 RECEPTOR; PURINE P2X RECEPTOR; PURINE P2X7 RECEPTOR; PURINE RECEPTOR; RECEPTOR SUBTYPE;

APOPTOSIS; BONE REMODELING; CELL FUNCTION; INFLAMMATION; MICROENVIRONMENT; NEUROTRANSMISSION; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION;

ADENOSINE TRIPHOSPHATE; ANIMALS; APOPTOSIS; BONE AND BONES; CELL NUCLEUS; HUMANS; OSTEOBLASTS; OSTEOCLASTS; RECEPTORS, PURINERGIC P2; SIGNAL TRANSDUCTION; UP-REGULATION;

JONES;

EID: 0345732699     PISSN: 10454403     EISSN: None     Source Type: Journal    
DOI: 10.1615/CritRevEukaryotGeneExpr.v13.i24.140     Document Type: Review

References (52)

1. 7 receptor expression in evolutive and indolent forms of chronic B lymphocytic leukemia. Blood 15:706-708.
2. Bowler WB, Birch MA, Gallagher JA, Bilbe G (1995): Identification and cloning of human P2u purinoceptor present in osteoclastoma, bone and osteoblasts. J Bone Miner Res 10:1137-1145.
3. Bowler WB, Tattersall JA, Hussein R, Dixon CJ, Cobbold PH, Gallagher JA (1998a): Real time measurement of ATP release from human osteoblasts. J Bone Miner Res 13:525.
4. Bowler WB, Tattersall JA, Hussein R, Dixon CJ, Cobbold PH, Gallagher JA (1998b): Release of ATP by osteoblasts: modulation by fluid shear forces. Bone 22:3S.
5. Bowler WB, Littlewood-Evans A, Bilbe G, Gallagher JA, Dixon CJ (1998c): P2Y2 receptors are expressed by human osteoclasts of giant cell tumor but do not mediate ATP-induced bone resorption. Bone 22: 195-200.
6. 2+ mobilization is strongly potentiated by a parathyroid hormone/cAMP-dependent protein kinase pathway independently of mitogen-activated protein kinase. J Biol Chem 274:14315-14324.
7. Bowler WB, Buckley KA, Gartland A, Hipskind RA, Bilbe G, Gallagher JA (2001): Extracellular nucleotide signaling: a mechanism for integrating local and systemic responses in the activation of bone remodeling. Bone 28:507-512.
8. Buckley KA, Golding SL, Rice JM, Dillon JP, Gallagher JA (2003): Release and interconversion of P2 receptor agonists; by human osteoblast-like cells. FASEB J 17(11): 1401-1410.
9. Buckley KA, Hipskind RA, Gartland A, Bowler WB, Gallagher JA (2002): ATP stimulates human osteoclast activity via upregulation of osteoblast-expressed RANKL. Bone 31:582-590.
10. Buckley KA, Wagstaff SC, McKay G, Gaw A, Hipskind RA, Bilbe G, Gallagher JA, Bowler WB (2001): Parathyroid hormone potentiates nucleotide-induced [Ca2+] i release in rat osteoblasts independently of Gq activation or cyclic monophosphate accumulation. A mechanism for localizing systemic responses in bone. J Biol Chem 276:9565-9571.
11. 7 receptor function with a monoclonal antibody. Blood 92:3521-3528.
12. Burnstock G (1972): Purinergic nerves. Pharmacol Rev 24: 509-581.
13. Burnstock G (1976): Do some nerve cells release more than one transmitter? Neuroscience 1:239-248.
14. Burnstock G (1978): A basis for distinguishing two types of purinergic receptor. In Straub RW, Bolis L (eds): Cell membrane receptors for drugs and hormones: a multidisciplinary approach. New York: Raven Press.
15. Chaib N, Kabre E, Alzola E, Pochet S, Dehaye JP (2000): Bromoenol lactone enhances the permeabilization of rat submandibular acinar cells by P2X7 agonists. Br J Pharmacol 129:703-708.
16. Chessell IP, Michel AD, Humphrey PPA (1998): Effects of antagonist at the human recombinant P2X7 receptor. Br J Pharmacol 124:1314-1320.
17. Chow SC, Kass GEN, Orrenius S (1997): Purines and their role in apoptosis. Neuropharmacology 36:1149-1156.
18. Dixon SJ, Sims SM (2000): P2 purinergic receptors on osteoblasts and osteoclasts: potential targets for drug development. Drug Dev Res 49:187-200.
19. Drury AN, Szent-Györgyi A (1929): The physiological actions of extracellular adenine compounds with special reference to their action upon the mammalian heart. J Physiol 68:213-237.
20. Edwards FA, Gibb AJ, Colquhoun D (1992): ATP receptor mediated synaptic currents in the central nervous system. Nature 359:144-147.
21. Fredholm BB, Abbracchio MP, Burnstock G, Daly JW, Harden TK, Jacobson KA, Leff P, Williams M (1994): Nomenclature and classification of purinoceptors. Pharmacol Rev 64:143-156.
22. Gartland A, Gallagher JA, Bowler WB (2001a): Blockade of P2X7 receptors inhibits osteoclast fusion in vitro. Bone 28:P294.
23. 7 receptor by a sub-population of human osteoblasts. J Bone Miner Res 16:846-856.
24. Gartland A, Buckley KA, Hipskind RA, Perry MJ, Tobias JH, Buell G, Chessel I, Bowler WB, Gallagher JA (2002): P2X(7) receptor-deficient mice maintain the ability to form multinucleated osteoclasts in vivo and in vitro. J Bone Miner Res 17:P35.
25. 7 receptor inhibits formation of multinucleated human osteoclasts in vitro. Calcif Tissue Int. July 24, 2003. Available online: DOI: 10.1007/s00223-002-2098-y.
26. Gartland A, Buckley KA, Hipskind RA, Perry MJ, Tobias JH, Buell G, Chessel I, Bowler WB, Gallagher JA (2003b): Multinucleated osteoclast formation in vivo and in vitro by P2X7 receptor-deficient mice. Crit Rev Eukaryotic Gene Expr 13(2-4):243-253.
27. Green HN, Stoner HB (1950): Biological actions of the adenine nucleotides. London: Lewis.
28. Haynes DR, Crotti TN, Loric M, Bain GI, Atkins GJ, Findlay DM (2001): Osteoprotegerin and receptor activator of nuclear factor kappaB ligand (RANKL) regulate osteoclast formation by cells in the human rheumatoid arthritic joint. Rheumatology 40:623-630.
29. Hoebertz A, Mahendran S, Burnstock G, Arnett TR (2002): ATP and UTP at low concentrations strongly inhibit bone formation by osteoblasts: a novel role for the P2Y2 receptor in bone remodeling. J Cell Biochem 86: 413-419.
30. Hoebertz A, Meghji S, Burnstock G, Arnett TR (2001) Extracellular ADP is a powerful osteolytic agent: evidence for signaling through the P2Y(1) receptor on bone cells. FASEB J 15:1139-1148.
31. Humphreys BD, Virginio C, Surprenant A, Rice J, Dubyak GR (1998): Isoquinolines as antagonists of the P2X7 nucleotide receptor: high selectivity for the human versus rat receptor homologues. Mol Pharmacol 54:22-32.
32. Jones SJ, Gray C, Boyde A, Burnstock G (1997): Purinergic transmitters inhibit bone formation by cultured osteoblasts. Bone 21:393-399.
33. Jorgensen NR, Henriksen Z, Sorensen OH, Eriksen EF, Civitelli R, Steinberg TH (2002): Intercellular calcium signaling occurs between human osteoblasts and osteoclasts and requires activation of osteoclast P2X7 receptors. J Biol Chem 277:7574-7580.
34. Kon T, Cho TJ, Aizawa T, Yamazaki M, Nooh N, Graves D, Gerstenfeld LC, Einhorn TA (2001): Expression of osteoprotegerin, receptor activator of NF-kappaB ligand (osteoprotegerin ligand) and related proinflammatory cytokines during fracture healing. J Bone Miner Res 16:1004-1014.
35. Kumagi H, Sacktor B, Filburn CR (1991): Purinergic regulation of cytosolic calcium and phosphoinositide metabolism in rat osteoblast-like osteosarcoma cells. J Bone Miner Res 6:697-707.
36. Michel AD, Xing M, Humphrey PP (2001): Serum constituents can affect 2′-&3′-O-(4-benzoylbenzoyl)-ATP potency at P2X(7) receptors. Br J Pharmacol 132: 1501-1508.
37. Mizuno K, Okamoto H, Horio T (2001): Heightened ability of monocytes from sarcoidosis patients to form multinucleated giant cells in vitro by supernatants of concanavalin A-stimulated mononuclear cells. Clin Exp Immunol 126:151-156.
38. 4-: elimination of osteoclasts, macrophages, and their precursors from isolated bone cell populations and fetal bone rudiments. Calcif Tissue Int 55:141-150.
39. Morrison MS, Turin L, King BF, Burnstock G, Arnett TR (1998): ATP is a potent stimulator of the activation and formation of rodent osteoclasts. J Physiol 511:495-500.
40. Naemsch LN, Weidema AF, Sims SM, Underhill TM, Dixon SJ (1999): P2X(4) purinoceptors mediate an ATP-activated, non-selective cation current in rabbit osteoclasts. J Cell Sci 112:4425-4435.
41. Naemsch LN, Dixon SJ, Sims SM. (2001): Activity-dependent development of P2X7 current and Ca2+ entry in rabbit osteoclasts. J Biol Chem 276:39107-39114.
42. Olmsted EA, Gannon FH, Wang ZQ, Grigoriadis AE, Wagner EF, Zasloff MA, Shore EM, Kaplan FS (1998): Embryonic overexpression of the c-Fos protooncogene. A murine stem cell chimera applicable to the study of fibrodysplasia ossificans progressiva in humans. Clin Orthop 346:81-94.
43. Perregaux D, Gabel CA (1994): Interleukin-1β maturation and release in response to ATP and nigericin. J Biol Chem 21:15195-15203.
44. Romanello M, Pani B, Bicego M, D'Andrea P (2001): Mechanically induced ATP release from human osteoblastic cells. Biochem Biophys Res Commun 289: 1275-1281.
45. 2 receptor on human osteoblast-like cells. J Bone Miner Res 7:485-491.
46. Shimegi S (1996): ATP and adenosine act as a mitogen for osteoblast-like cells (MC3T3-E1). Calcif Tissue Int 58:109-113.
47. 4- permeabilizes the plasma-membrane of mouse macrophages to fluorescent dyes. J Biol Chem 262:8884-8888.
48. Wang ZQ, Ovitt C, Grigoriadis AE, Mohlesteinlein U, Ruther U, Wagner EF (1992): Bone and haematopoietic defects in mice lacking c-fos. Nature 360:741-745.
49. Wiebe SH, Sims SM, Dixon SJ (1999): Calcium signalling via multiple P2 purinoceptor subtypes in rat osteoclasts. Cell Physiol Biochem 9:323-337.
50. Wiley JS, Gargett CE, Zhang W, Snook MB, Jamieson GP (1998): Partial agonists and antagonists reveal a second permeability state of human lymphocyte P2Z/P2X7 channel. Am J Physiol 275:C1224-1231.
51. Yu H, Ferrier J (1993): Osteoblast-like cells have a variable mixed population of purino/nucleotide receptors. FEBS Lett 328:209-214.
52. Yu H, Ferrier J (1994): Mechanisms of ATP-induced Ca2+ signaling in osteoclasts. Cell Signal 6:905-914.